Clinical Trial Update: Lung Injury is One of the Primary Causes of Morbidity and Mortality in Critically Ill Patients. These Patients Will be Monitored for: 1) Immune Cell Activation 2) Blood-based Biomarkers. In Vitro Models Derived From These Samples Will be Treated With Novel Agent PIP-2 to Evaluate Its Efficacy.

View source ↗

Summary

A clinical trial focusing on ARDS risk and monitoring immune activation and blood biomarkers, with in vitro samples treated with the novel agent PIP-2 to evalua…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• PIP-2 (PIP-2)

Snippet

Sponsor: University of Pennsylvania | Conditions: ARDS (Acute Respiratory Distress Syndrome) | Status: RECRUITING